Literature DB >> 7061906

[Clinical effect of gamma-oryzanol on climacteric disturbance -on serum lipid peroxides (author's transl)].

M Ishihara, Y Ito, T Nakakita, T Maehama, S Hieda, K Yamamoto, N Ueno.   

Abstract

Though gamma-Oryzanol has been applicated as the autonomic agent in various fields for a few decades, recently its effect on lipid metabolism comes to be much more interested. We studied on the effect of gamma-Oryzanol on climacteric disturbance, and besides on the difference of lipid peroxides level which has an important and indispensable connection with mary syndromes involving aging. We obtained the following results from 40 subjects with climacteric disturbance after administration of gamma-Oryzanol Fine Particule 1.5 g (gamma-Oryzanol 300 mg included) for 4 to 8 weeks. 1. 90% of the cases improved generally; Excellent 16 (40%), Good 14 (35%), Effective 6 (15%), No change 4 (10%). 2. Effect on climacteric disturbance was judged by the Kupperman method and the Ueda method; generally recovered 85%, 80% each. 3. Significantly reduced total cholesterol, triglyceride and increased HDL-cholesterol were noted in cases with hyperlipidemia (TC greater than or equal to 220 mg/dl, TG greater than or equal to 140 mg/dl, HDL-chol. less than or equal to 45 mg/dl). Therefore, atherogenic index was excellently recovered. 4. In cases with climacteric disturbance lipid peroxides level was high, and they were significantly recovered by administration of gamma-Oryzanol. 5. During this study, no side effects have been recognized and no particular change in function test was found. Thus, we confirmed the efficacy and utility of gamma-Oryzanol on many complaints in climacteric disturbance and also on lipid metabolism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7061906

Source DB:  PubMed          Journal:  Nihon Sanka Fujinka Gakkai Zasshi        ISSN: 0300-9165


  3 in total

1.  Definitive evidence of the presence of 24-methylenecycloartanyl ferulate and 24-methylenecycloartanyl caffeate in barley.

Authors:  Junya Ito; Kazue Sawada; Yusuke Ogura; Fan Xinyi; Halida Rahmania; Tomoyo Mohri; Noriko Kohyama; Eunsang Kwon; Takahiro Eitsuka; Hiroyuki Hashimoto; Shigefumi Kuwahara; Teruo Miyazawa; Kiyotaka Nakagawa
Journal:  Sci Rep       Date:  2019-08-29       Impact factor: 4.379

2.  Neuronal Induction of Bone-Fat Imbalance through Osteocyte Neuropeptide Y.

Authors:  Yan Zhang; Chun-Yuan Chen; Yi-Wei Liu; Shan-Shan Rao; Yi-Juan Tan; Yu-Xuan Qian; Kun Xia; Jie Huang; Xi-Xi Liu; Chun-Gu Hong; Hao Yin; Jia Cao; Shi-Kai Feng; Ze-Hui He; You-You Li; Zhong-Wei Luo; Ben Wu; Zi-Qi Yan; Tuan-Hui Chen; Meng-Lu Chen; Yi-Yi Wang; Zhen-Xing Wang; Zheng-Zhao Liu; Ming-Jie Luo; Xiong-Ke Hu; Ling Jin; Teng-Fei Wan; Tao Yue; Si-Yuan Tang; Hui Xie
Journal:  Adv Sci (Weinh)       Date:  2021-10-31       Impact factor: 16.806

3.  African derived phytocompounds may interfere with SARS-CoV-2 RNA capping machinery via inhibition of 2'-O-ribose methyltransferase: An in silico perspective.

Authors:  Gideon A Gyebi; Oludare M Ogunyemi; Adedotun A Adefolalu; Alejandro Rodríguez-Martínez; Juan F López-Pastor; Antonio J Banegas-Luna; Horacio Pérez-Sánchez; Adegbenro P Adegunloye; Olalekan B Ogunro; Saheed O Afolabi
Journal:  J Mol Struct       Date:  2022-04-12       Impact factor: 3.841

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.